BeiGene, Ltd. (BGNE)
Largest Insider Buys in Sector
BGNE Stock Price History Chart
BGNE Stock Performance
About BeiGene, Ltd.
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; …
Insider Activity of BeiGene, Ltd.
Over the last 12 months, insiders at BeiGene, Ltd. have bought $0 and sold $223.95M worth of BeiGene, Ltd. stock.
On average, over the past 5 years, insiders at BeiGene, Ltd. have bought $50M and sold $367.98M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 165,529 shares for transaction amount of $50M was made by AMGEN INC (10 percent owner) on 2021‑09‑10.
List of Insider Buy and Sell Transactions, BeiGene, Ltd.
| 2024-10-08 | Sale | Chief Executive Officer | 15,279 0.0152% | $231.97 | $3.54M | -6.79% | ||
| 2024-09-30 | Sale | SVP, General Counsel | 1,202 0.0012% | $237.10 | $284,994 | +0.14% | ||
| 2024-09-27 | Sale | Global Head of R&D | 5,000 0.0047% | $220.35 | $1.1M | +2.79% | ||
| 2024-09-19 | Sale | President, COO & GM China | 4,500 0.0041% | $200.14 | $900,615 | +11.98% | ||
| 2024-09-17 | Sale | President, COO & GM China | 500 0.0005% | $200.00 | $100,000 | +11.91% | ||
| 2024-09-03 | Sale | President, COO & GM China | 5,556 0.005% | $189.65 | $1.05M | +12.82% | ||
| 2024-09-03 | Sale | Principal Accounting Officer | 137 0.0001% | $189.94 | $26,022 | +12.82% | ||
| 2024-07-30 | Sale | SVP, General Counsel | 834 0.0008% | $160.57 | $133,915 | +1.07% | ||
| 2024-07-01 | Sale | Chief Financial Officer | 472 0.0004% | $143.90 | $67,919 | 0.00% | ||
| 2024-06-24 | Sale | President, COO & GM China | 1,459 0.0014% | $159.79 | $233,133 | +24.16% | ||
| 2024-06-24 | Sale | Global Head of R&D | 1,064 0.001% | $159.80 | $170,030 | +24.16% | ||
| 2024-06-24 | Sale | Chief Financial Officer | 899 0.0008% | $155.66 | $139,938 | +24.16% | ||
| 2024-06-24 | Sale | Chief Executive Officer | 2,789 0.0026% | $159.58 | $445,070 | +24.16% | ||
| 2024-06-18 | Sale | President, COO & GM China | 2,627 0.0023% | $154.36 | $405,516 | +27.52% | ||
| 2024-06-18 | Sale | Global Head of R&D | 841 0.0007% | $153.75 | $129,305 | +27.52% | ||
| 2024-06-17 | Sale | President, COO & GM China | 627 0.0006% | $159.00 | $99,692 | +23.52% | ||
| 2024-06-17 | Sale | Global Head of R&D | 1,500 0.0013% | $159.24 | $238,857 | +23.52% | ||
| 2024-06-17 | Sale | Chief Financial Officer | 916 0.0008% | $159.04 | $145,678 | +23.52% | ||
| 2024-06-17 | Sale | Chief Executive Officer | 1,281 0.0012% | $159.35 | $204,125 | +23.52% | ||
| 2024-06-17 | Sale | SVP, General Counsel | 439 0.0004% | $159.35 | $69,955 | +23.52% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | 877603 0.7956% | $203.22 | 5 | 3 | +24.57% | |
| Hillhouse Capital Management, Ltd. | 10 percent owner | 39726779 36.0152% | $203.22 | 1 | 0 | <0.0001% |
| AMGEN INC | 10 percent owner | 18943802 17.1739% | $203.22 | 1 | 0 | <0.0001% |
| Yuan RuiRong | Chief Medical Officer | 130000 0.1179% | $203.22 | 1 | 0 | <0.0001% |
| Malley Thomas | director | 30000 0.0272% | $203.22 | 1 | 0 | +25.31% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $1.65B | 9.99 | 10.57M | 0% | +$0 | 11.87 | |
| Capital International Investors | $1.1B | 6.68 | 7.06M | +11.48% | +$113.78M | 0.22 | |
| Hillhouse Capital Advisors Ltd | $809.62M | 4.89 | 5.18M | 0% | +$0 | 17.63 | |
| PRIMECAP Management Co | $782.24M | 4.73 | 5M | +0.27% | +$2.06M | 0.57 | |
| Baillie Gifford Co | $583.14M | 3.52 | 3.73M | -3.56% | -$21.54M | 0.45 |